Skip to content

Assessing the therapeutic effect of probiotics on individuals in mild cognitive impairment.

Assessing the therapeutic effect of probiotics on individuals with mild cognitive impairment at Korle - Bu Teaching Hospital.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
PACTR
Registry ID
PACTR202305650866475
Enrollment
120
Registered
2023-05-16
Start date
2023-05-22
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental and Behavioural Disorders

Interventions

Mild cognitive impairment group
Placebo

Sponsors

WESTERN SYDNEY UNIVERSITY
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: • The subject is between 50-75 years old. • The subject is clinically diagnosed with Mild cognitive impairment by the Neurologist. • The subject's MoCA score is between 10-26. • The subject can cooperate to perform cognitive function tests. • The subject has dependable caregivers who can record the compliance of taking probiotics and any physical conditions. • The subject or family members signed the informed consent form and answered the questionnaire.

Exclusion criteria

Exclusion criteria: • The subject has dementia caused by other reasons, such as brain trauma, tumour, infection, epilepsy, etc. • The subject has consumed probiotic-related products (probiotic powder, yoghurt or other fermented foods) within the past 1 month. • The subject has participated in clinical trials of other dementia medications in the past 1 month. • The subject is assessed for dementia caused by vitamin B12 deficiency or thyroid abnormalities. • The subject suffers from mental illness, severe depression, schizophrenia, drug addiction, and alcohol addiction. • The subject has Parkinson's disease. • The subject is assessed to have severe metabolic and liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
?cognitive function measured using an appropriate, validated cognitive test, gut microbiota diversity and composition

Secondary

MeasureTime frame
? changes in metabolic variables, Biomarkers and cognitive function ? Randomized controlled trials (RCTs) and clinical controlled trials (CCTs)

Countries

Ghana

Contacts

Public ContactPatrick Adjei

Head of Medicine department of Korle Bu Teaching Hospital

PAdjei@ug.edu.gh+233549581079

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026